1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Nocturnal Enuresis Global Clinical Trials Review, H2, 2015

Nocturnal Enuresis Global Clinical Trials Review, H2, 2015

  • September 2015
  • -
  • Global Data
  • -
  • 42 pages

Nocturnal Enuresis Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Nocturnal Enuresis Global Clinical Trials Review, H2, 2015" provides an overview of Nocturnal Enuresis clinical trials scenario. This report provides top line data relating to the clinical trials on Nocturnal Enuresis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Nocturnal Enuresis Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Asia-Pacific 8
Top Five Countries Contributing to Clinical Trials in Europe 9
Top Countries Contributing to Clinical Trials in North America 10
Top Countries Contributing to Clinical Trials in Middle East and Africa 11
Clinical Trials by G7 Countries: Proportion of Nocturnal Enuresis to Genito Urinary System And Sex Hormones Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by E7 Countries: Proportion of Nocturnal Enuresis to Genito Urinary System And Sex Hormones Clinical Trials 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Subjects Recruited Over a Period of Time 20
Clinical Trials by Sponsor Type 21
Prominent Sponsors 22
Top Companies Participating in Nocturnal Enuresis Therapeutics Clinical Trials 23
Prominent Drugs 24
Clinical Trial Profile Snapshots 25
Appendix 39
Abbreviations 39
Definitions 39
Research Methodology 40
Secondary Research 40
About GlobalData 41
Contact Us 41
Disclaimer 41
Source 42

List of Tables
Nocturnal Enuresis Therapeutics, Global, Clinical Trials by Region, 2015* 5
Nocturnal Enuresis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 6
Nocturnal Enuresis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 7
Nocturnal Enuresis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 8
Nocturnal Enuresis Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 9
Nocturnal Enuresis Therapeutics Clinical Trials, North America, Top Countries, 2015* 10
Nocturnal Enuresis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 11
Proportion of Nocturnal Enuresis to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2015* 12
Nocturnal Enuresis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 13
Nocturnal Enuresis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 14
Proportion of Nocturnal Enuresis to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2015* 15
Nocturnal Enuresis Therapeutics, Global, Clinical Trials by Phase, 2015* 16
Nocturnal Enuresis Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 17
Nocturnal Enuresis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 18
Nocturnal Enuresis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 19
Nocturnal Enuresis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 20
Nocturnal Enuresis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 21
Nocturnal Enuresis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 22
Nocturnal Enuresis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 23
Nocturnal Enuresis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 24

List of Figures
Nocturnal Enuresis Therapeutics, Global, Clinical Trials by Region (%), 2015* 5
Nocturnal Enuresis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 6
Nocturnal Enuresis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 7
Nocturnal Enuresis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 8
Nocturnal Enuresis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 9
Nocturnal Enuresis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 11
Proportion of Nocturnal Enuresis to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2015* 12
Nocturnal Enuresis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 13
Nocturnal Enuresis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 14
Proportion of Nocturnal Enuresis to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2015* 15
Nocturnal Enuresis Therapeutics, Global, Clinical Trials by Phase (%), 2015* 16
Nocturnal Enuresis Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 17
Nocturnal Enuresis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 18
Nocturnal Enuresis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 20
Nocturnal Enuresis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 21
Nocturnal Enuresis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 22
Nocturnal Enuresis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 23
Nocturnal Enuresis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 24
GlobalData Methodology 40

Companies Mentioned
Ferring International Center S.A.
Vantia Therapeutics
Lipotec SA
Eli Lilly and Company

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

  • $ 34500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 925 pages and 366 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in Sweden

  • February 2017
    8 pages
  • Therapy  

    Hormone  

    Antidiabetics  

  • Sweden  

View report >

Insulin Market and Diabetes Statistics in the US

  • February 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Hormone and Therapy Market in Pakistan and the US

  • February 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Related Market Segments :

Hormone
Hormones

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.